Eris Lifesciences Limited (BOM:540596)

Market Cap	244.15B
Revenue (ttm)	29.35B
Net Income (ttm)	3.87B
Shares Out	n/a
EPS (ttm)	28.36
PE Ratio	63.17
Forward PE	40.86
Dividend	7.35 (0.41%)
Ex-Dividend Date	Feb 13, 2025

Volume	898
Average Volume	5,984
Open	1,800.35
Previous Close	1,801.00
Day's Range	1,768.50 - 1,812.00
52-Week Range	1,130.05 - 1,909.55
Beta	n/a
RSI	57.39
Earnings Date	Aug 4, 2025

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electro...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 3,354
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540596

Financial Performance

In 2024, Eris Lifesciences's revenue was 28.79 billion, an increase of 44.59% compared to the previous year's 19.91 billion. Earnings were 3.52 billion, a decrease of -10.26%.